Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Synovitis and enthesitis are key manifestations in psoriatic arthritis (PsA). This descriptive analysis investigated the association between improvement in synovitis and enthesitis, individually and combined, and improvement in patient-reported outcomes (PROs) including health-related quality of life (HRQoL) for patients with PsA from the SPIRIT-P1, SPIRIT-P2, and SPIRIT-H2H trials who presented with synovitis and enthesitis at baseline and received ixekizumab (IXE) treatment.
Methods: In this post hoc analysis, data are presented from patients with PsA treated with IXE every 4 weeks from two phase III studies (SPIRIT-P1 and SPIRIT-P2) and one phase IIIb/IV study (SPIRIT-H2H) who had both synovitis and enthesitis at baseline. Associations between improvements in synovitis and improvements in enthesitis were explored using Pearson analyses through week 52. Associations between improvements in both, either, and neither condition with improvements in PROs (36-item Short Form Health Survey Physical Component Score [SF-36 PCS], the European Quality-of-Life 5 Dimensions 5 Levels [EQ-5D-5L] including the EQ-5D Visual Analogue Score [VAS] and the EQ-health index, Patient's Global Assessment [PtGA], and pain VAS) were assessed descriptively through week 52.
Results: Results demonstrated the synergistic improvements in synovitis and enthesitis, individually or combined, and improvements in PROs including HRQoL, for patients treated with IXE through week 52. An association between improvements in synovitis and enthesitis symptoms was observed through week 52. Patients who achieved resolution of both synovitis and enthesitis reported highest improvements in SF-36 PCS, EQ-5D-5L, pain VAS, and PtGA.
Conclusion: Synergistic improvements in two key PsA domains, namely synovitis and enthesitis, and improvements in PROs including HRQoL, were observed for patients with PsA treated with IXE through week 52. These findings support PsA treatment goal aiming to achieve the lowest possible level of disease activity in all disease domains.
Trial Registration Numbers: SPIRIT-P1 (NCT01695239), SPIRIT-P2 (NCT02349295), and SPIRIT-H2H (NCT03151551).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920489 | PMC |
| http://dx.doi.org/10.1007/s40744-025-00748-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Biologics on synovitis and enthesitis using Musculoskeletal ultrasound assessment in subclinical psoriatic arthritis: A 12-week observational real-world study.
J Am Acad Dermatol
September 2025
Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350000, People's Republic of China; Key Laboratory of skin cancer of Fujian higher education institutions, Fuzhou, Fujian 350000, People's Republic of China; Fujian Provincial Clinical Research Cent
Background: Psoriatic arthritis (PsA) is a condition that can lead to permanent joint deformities. It is crucial to find ways to prevent psoriasis (PsO) from progressing to PsA.
Objectives: To observe the short-term efficacy of biologics on synovitis and enthesitis in subclinical psoriatic arthritis (Sub-PsA) using musculoskeletal ultrasound (MSUS).
Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index.
Reumatol Clin (Engl Ed)
September 2025
Rheumatology Unit, Hospital Universitari Vall Hebron, Spain.
Background: Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast.
Primary Objective: 20% reduction in the US index (UIC) at 12 months.
Rheumatic Manifestations in Patients with Idiopathic Inflammatory Bowel Disease: A Single Tertiary Centre, Interdisciplinary Study.
Mediterr J Rheumatol
June 2025
Department of Gastroenterology.
Background: Inflammatory bowel disease is closely associated with extraintestinal manifestations. Among them, joint involvement and enthesitis are the most frequent resembling a spondyloarthropathy. Enthesitis may be clinically silent in a high proportion of these patients without any clinical signs or a diagnosis of spondyloarthritis.
View Article and Find Full Text PDFAssociation of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients: A Cross-sectional Study.
J Rheumatol
July 2025
L. Eder, Associate Professor, MD, Department of Medicine, University of Toronto, Division of Rheumatology, Women's College Hospital, Toronto, ON; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Objective: Ultrasound can enhance Psoriatic Arthritis (PsA) disease activity assessment, but the impact of contextual factors on sonographic findings in PsA remains unclear. This study examines how demographic and clinical factors affect sonographic lesions in active PsA.
Methods: Cross-sectional study of 115 active PsA patients who underwent US evaluation for synovitis, enthesitis, peritenonitis, tenosynovitis, bone erosion, and new bone formation (NBF).
Role of ultrasound in the interception of psoriatic arthritis in patients with psoriasis.
Clin Exp Rheumatol
July 2025
Rheumatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Skin psoriasis (PsO) often precedes the development of psoriatic arthritis (PsA), with a PsO to PsA conversion rate of about 1.5-2% per year. A careful observation of the PsO patients may allow early detection, treatment, and maybe even prevention, of the rheumatic condition.
View Article and Find Full Text PDF